Zealand Pharma Receives Notification from Major Shareholder Van Herk Investments B.V.

Strategic Insights -

Van Herk Investments B.V. has notified Zealand Pharma A/S of its holding of nominally 7,115,191 shares, equivalent to 9.973% of the total share capital and 9.973% of the total voting rights in the company. This significant shareholder holds its shares through a complex ownership structure, ultimately controlled by Mr. Adrianus van Herk. The company, which has developed over 10 drug candidates, including two commercialized products and three candidates in late-stage development, continues to advance its peptide-based medicines.

Key Takeaways:

  • Van Herk Investments B.V. holds 7,115,191 shares in Zealand Pharma A/S, representing 9.973% of the total share capital and 9.973% of the total voting rights.
  • The company's complex ownership structure ultimately leads to Mr. Adrianus van Herk being the controlling owner.
  • Zealand Pharma A/S has developed over 10 drug candidates, including two commercialized products and three candidates in late-stage development.
  • The company has development partnerships with several pharmaceutical companies and commercial partnerships for its marketed products.
  • Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States.

Statistics:

  • Zealand Pharma A/S has over 10 drug candidates in clinical development.
  • Two of the company's drug candidates have reached the market.
  • Three of its candidates are in late-stage development.
  • The company has development partnerships with several pharmaceutical companies.
  • Zealand has a presence in both Denmark and the United States.

Sources:

  • Zealand Pharma announcement No. 19 / 2025.
  • Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines.
  • About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.